RIBOLIFE-B (06938) announced its 2025 financial results, achieving revenue of approximately 1.485 billion yuan, representing a 4.1% increase compared to the previous year. Gross profit reached about 1.35 billion yuan, up 3.3% year-on-year. Research and development expenses were approximately 280 million yuan, remaining largely stable.

The growth in revenue was primarily driven by increased income from the collaboration with Boehringer Ingelheim and sales of nucleoside monomer-related products through Xingborun. To date, the company has advanced seven self-developed siRNA candidate drugs into clinical stages, establishing itself as a global leader in the field of small nucleic acid drug development. Beyond its clinical pipeline, the company maintains over 20 preclinical projects progressing toward clinical development.

Since its establishment, the company has entered into multiple licensing and collaboration agreements with Boehringer Ingelheim and Qilu Pharmaceutical, with a total transaction value exceeding $2.1 billion. Prior to the end of the reporting period, the company achieved two R&D milestones in its transaction with Boehringer Ingelheim and one R&D milestone in its agreement with Qilu Pharmaceutical.

In February 2026, the company entered into a new global licensing agreement with Madrigal for six preclinical siRNA projects targeting MASH treatment. Under this agreement, RIBOLIFE-B granted Madrigal exclusive global rights to develop, manufacture, and commercialize certain siRNA assets. Upon achieving specified development, regulatory, and commercial milestones, the company will receive an upfront payment of $60 million and cumulative payments totaling $4.4 billion, including the upfront and milestone payments, in addition to royalties based on global net sales of the collaborative products.

As of the end of the reporting period, the company held 255 patents, including 62 granted patents in China, 65 in Europe, 18 in the United States, and 110 in other jurisdictions. It also had 218 patent applications, comprising 77 in China, 17 in Europe, 19 in the United States, 22 under the Patent Cooperation Treaty (PCT), and 83 in other jurisdictions.